A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

Recruiting now. Registry record last updated August 21, 2026.

Who can join: Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.
What you take: orforglipron, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2.7 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 3Sponsor Eli Lilly and CompanyDrug orforglipronClass GLP-1 RASites 35 USEnrollment target 1,205

What this study is for

Primary condition: Peripheral Arterial Disease.

Full scientific study title: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease.

Who can join

Age18 and upSexAnyBMI23 or higher

Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Have symptomatic PAD with intermittent claudication of Fontaine Stage II
Have an Ankle Brachial Index (ABI) of 0.9 or less

Key exclusion criteria

Have a body mass index (BMI) less than 23 kilogram per square meter (kg/m2)
Have Hemoglobin A1c (HbA1c) greater than 10%
Have walking ability limited by conditions other than PAD
Have a planned lower limb surgery or any other surgery affecting walking ability
Had peripheral revascularization procedure within 90 days prior to the day of screening or planning to undergo peripheral revascularization during the clinical trial

Where this trial is enrolling

This trial has 35 sites across 14 states. Contact a site coordinator directly to start screening.

Find a site near you

Alabama1 site

St. Vincent's Birmingham Hospital
Birmingham, Alabama

Arizona3 sites

Mercy Gilbert Medical Center
Gilbert, Arizona
602-214-0886
Emvera Health at Peak Heart & Vascular Surprise
Surprise, Arizona
844-290-2273
Del Sol Research Management, LLC
Tucson, Arizona
520-257-3881

California5 sites

Angel City Research Inc.
Los Angeles, California
213-365-0793
Valley Clinical Trials, LLC dba Flourish Research
Northridge, California
818-280-4220
The Cardiovascular Center
Redding, California
281-944-3610
InvivoCure
Van Nuys, California
859-509-0084
Interventional Cardiology Medical Group
West Hills, California
818-702-8800

Colorado1 site

Rocky Mountain Regional VA Medical Center
Aurora, Colorado

Florida4 sites

Lakeview Institute of Clinical Research
Leesburg, Florida
352-782-0606
Inpatient Research Clinic
Miami Lakes, Florida
786-502-4303
Floridian Clinical Research, LLC
Miami Lakes, Florida
305-330-9977
St Johns Center for Clinical Research
Saint Augustine, Florida
904-209-0043

Indiana4 sites

ASHA Clinical Research - Munster, LLC
Hammond, Indiana
219-803-6649
Indiana University Health Methodist Hospital
Indianapolis, Indiana
Cardiovascular Research of Northwest Indiana
Munster, Indiana
219-934-4200
Deaconess Clinic- Gateway
Newburgh, Indiana
812-490-4505

Maryland2 sites

Flourish Research - Bowie
Bowie, Maryland
410-824-1341
Capitol Cardiology Associates - Lanham Office
Lanham, Maryland
561-906-0904

Michigan1 site

Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan
248-312-0025

Pennsylvania1 site

Capital Area Research, LLC
Camp Hill, Pennsylvania
717-441-1725

Tennessee2 sites

The Jackson Clinic
Jackson, Tennessee
731-660-8396
East Coast Institute for Research - Jefferson City
Jefferson City, Tennessee

Texas4 sites

Biopharma Informatic, LLC
Houston, Texas
281-944-3610
Research Physicians Network, LLC
Houston, Texas
832-847-1724
Sherman Clinical Research
Sherman, Texas
903-771-4093
NextStage Clinical Research - Waco
Waco, Texas

Utah1 site

Alpine Research Organization
Clinton, Utah
801-791-2206

Virginia4 sites

Stroobants Cardiovascular Center
Lynchburg, Virginia
Carient Heart & Vascular - Manassas
Manassas, Virginia
703-335-8750
Clinical Research Partners, LLC
Richmond, Virginia
804-477-3045
Gershon Pain Specialists
Virginia Beach, Virginia
757-496-2050

Washington2 sites

ERA Health Research - CardioNow - Lynnwood
Lynnwood, Washington
425-869-6828
Eastside Research Associates
Redmond, Washington
425-869-6828

Follow this trial

We email you if NCT07223593 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: October 31, 2025. Expected completion: June 2028. Last updated on ClinicalTrials.gov: August 21, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.